ECSP034504A - Derivados de acido oxazolil-arilpropionico y su uso como agonista ppar - Google Patents

Derivados de acido oxazolil-arilpropionico y su uso como agonista ppar

Info

Publication number
ECSP034504A
ECSP034504A EC2003004504A ECSP034504A ECSP034504A EC SP034504 A ECSP034504 A EC SP034504A EC 2003004504 A EC2003004504 A EC 2003004504A EC SP034504 A ECSP034504 A EC SP034504A EC SP034504 A ECSP034504 A EC SP034504A
Authority
EC
Ecuador
Prior art keywords
alkyl
unsubstituted
substituted
arilpropionic
oxazolil
Prior art date
Application number
EC2003004504A
Other languages
English (en)
Inventor
Leonard Larry Winneroski
Yanping Xu
Christopher John Rito
Alexander Glenn Godfrey
Dawn A Brooks
Sarah B Jones
James R Mccarthy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034504A publication Critical patent/ECSP034504A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos representados por la siguiente fórmula estructural (I) (Gráfico) y las sales, solvatos e hidratos farmacéuticamente aceptables de los mismos en la que n es 2, 3 ó 4 y W es CH2, CH(OH), C(O) o O; R1 es un arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o t-butilo no sustituido o sustituido; R2 es H, alquilo, haloalquilo o fenilo; Y es un tiofen-2,5- diilo o fenileno no sustituido o sustituido; R3 es alquilo o haloalquilo; R4 es un grupo fenilo, naftilo, 1, 2, 3, 4-tetrahidronaftilo, quinolilo, piridilo o benzo (1, 3) dioxol-5-ilo sustituido o no sustituido; y R5 es H, alquilo o aminoalquilo; son útiles para modular un receptor activado por proliferador de peroxisoma, particularmente en el tratamiento de la diabetes mellitus.
EC2003004504A 2000-08-23 2003-03-06 Derivados de acido oxazolil-arilpropionico y su uso como agonista ppar ECSP034504A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23

Publications (1)

Publication Number Publication Date
ECSP034504A true ECSP034504A (es) 2003-04-25

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004504A ECSP034504A (es) 2000-08-23 2003-03-06 Derivados de acido oxazolil-arilpropionico y su uso como agonista ppar

Country Status (26)

Country Link
US (2) US6930120B2 (es)
EP (1) EP1313716B1 (es)
JP (1) JP2004506721A (es)
KR (1) KR20030027054A (es)
CN (1) CN1471517A (es)
AT (1) ATE361283T1 (es)
AU (1) AU2001284659A1 (es)
BR (1) BR0113409A (es)
CA (1) CA2418104A1 (es)
CY (1) CY1107679T1 (es)
CZ (1) CZ2003482A3 (es)
DE (1) DE60128239T2 (es)
DK (1) DK1313716T3 (es)
EA (1) EA200300286A1 (es)
EC (1) ECSP034504A (es)
ES (1) ES2286137T3 (es)
HU (1) HUP0300857A3 (es)
IL (1) IL154110A0 (es)
MX (1) MXPA03001558A (es)
NO (1) NO20030729L (es)
NZ (1) NZ523804A (es)
PL (1) PL360744A1 (es)
PT (1) PT1313716E (es)
SK (1) SK1872003A3 (es)
WO (1) WO2002016331A1 (es)
ZA (1) ZA200300570B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131001T2 (de) 2000-08-23 2008-07-17 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
IL158589A0 (en) * 2001-05-15 2004-05-12 Hoffmann La Roche Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
EP1519925B1 (en) 2002-07-03 2007-09-12 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
KR100736955B1 (ko) 2002-08-30 2007-07-09 에프. 호프만-라 로슈 아게 Ppar알파 및 ppar감마 작용제로서의 신규한 2-아릴티아졸 화합물
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
WO2004041275A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
RU2315767C2 (ru) 2002-11-25 2008-01-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
US7662771B2 (en) * 2003-08-20 2010-02-16 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
DE69723680T9 (de) 1996-02-02 2004-11-04 Merck & Co., Inc. Antidiabetische mittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EP0930299A1 (en) * 1996-08-19 1999-07-21 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
ES2204684T3 (es) 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
DE60131001T2 (de) 2000-08-23 2008-07-17 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Also Published As

Publication number Publication date
HUP0300857A3 (en) 2007-03-28
DE60128239D1 (de) 2007-06-14
EP1313716A1 (en) 2003-05-28
KR20030027054A (ko) 2003-04-03
HUP0300857A2 (hu) 2003-10-28
NO20030729L (no) 2003-04-02
ES2286137T3 (es) 2007-12-01
NZ523804A (en) 2004-09-24
BR0113409A (pt) 2003-07-01
DK1313716T3 (da) 2007-08-27
WO2002016331A1 (en) 2002-02-28
SK1872003A3 (en) 2003-07-01
US20050245584A1 (en) 2005-11-03
ATE361283T1 (de) 2007-05-15
CY1107679T1 (el) 2013-04-18
US7345070B2 (en) 2008-03-18
EA200300286A1 (ru) 2003-08-28
JP2004506721A (ja) 2004-03-04
PT1313716E (pt) 2007-07-11
PL360744A1 (en) 2004-09-20
NO20030729D0 (no) 2003-02-14
IL154110A0 (en) 2003-07-31
US20040097590A1 (en) 2004-05-20
ZA200300570B (en) 2004-04-21
DE60128239T2 (de) 2008-01-10
MXPA03001558A (es) 2003-06-06
CN1471517A (zh) 2004-01-28
EP1313716B1 (en) 2007-05-02
US6930120B2 (en) 2005-08-16
AU2001284659A1 (en) 2002-03-04
CZ2003482A3 (cs) 2003-05-14
CA2418104A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ECSP034504A (es) Derivados de acido oxazolil-arilpropionico y su uso como agonista ppar
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
RU2006101890A (ru) Производные тиазолилпиперидина в качестве ингибиторов мпб
NO20022314D0 (no) Stabile forbindelser av nye derivater av 3,3- difenylpropylaminer
NO20022317L (no) Trifenylalkylen-derivater og deres anvendelse som selektive östrogen-reseptor-modulater
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
DE602004014347D1 (de) Chinazolin-derivate als tgf-beta-inhibitoren
ATE103592T1 (de) Carbamoylpyrrolidonderivate, ihre verwendung und herstellung.
CO4410319A1 (es) Derivados de fenetanolamina
ES2166269B1 (es) Nuevo procedimiento de obtencion de derivados de 2-(2-piridinilmetilsulfinil)-1h-benzimidazol.
SE9703379D0 (sv) New compounds
AR034206A1 (es) Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR040123A1 (es) Compuestos tiofeno, antihelminticos e insecticidas
DK1140761T3 (da) Benzophenoner og anvendelse deraf som fotoinitiatorer
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
ECSP055652A (es) Un nuevo proceso para la preparación de derivados de epotilona, nuevos derivados de epotilona, así como nuevos productos intermediarios para el proceso, y los métodos para su preparación
AR008920A1 (es) Proceso para la preparacion de los derivados de 2-amino-2-imidaxolina, guanidina, y 2-amino-3,4,5,6-tetrahidropiridimina
FI955933A (fi) Abeo-ergoliinijohdannaiset 5HT1A-ligandeina
ATE275560T1 (de) Bemzimidazolverbindungen und medikamente die diese enthalten
ES2162731B1 (es) Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
CO5280074A1 (es) Nuevos compuestos de piperidina-4,2 (1 h)-quinazolina, composiciones farmaceuticas que las contienen y proceso para su preparacion
CO4370120A1 (es) Tintas reactivas diazo, procesos para su preparacion y usos .
CY1107100T1 (el) ΚΙΝΝΑΜΩΜΙΚΑ ΠΑΡΑΓΩΓΑ ΒΕΝΖΟ[b] ΠΥΡΑΝΟ [3,2-h] ΑΚΡΙΔΙΝ-7-OΝΗΣ, ΜEΘΟΔΟΣ ΠΑΡΑΣΚΕΥHΣ ΑΥΤΩΝ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ
ECSP982603A (es) Nuevos compuestos heterociclicos
PE20020475A1 (es) Derivados de acido propionico como moduladores del receptor proliferador de peroxisoma ppar-o